Emphysema: Pulmonx hopes to pummel competition with Zephyr data
Privately held Pulmonx (Denver) said data from two recent studies provide evidence that could lead to doubling the amount of emphysema patients treated with its Zephyr Endobronchial Valve (EBV). The company presented at the American Thoracic Society (ATS; New York) Annual Meeting six-month results of the STELVIO trial and the VENT study, which demonstrated a statistically significant benefit in severe emphysema patients with homogeneous disease who received treatment with Zephyr.
Doctoring Twitter; HRS 2015 and social media
This year's edition of the Heart Rhythm Society annual scientific sessions is in the can, and there were a number of interesting related developments inside and outside the confines of the Boston Convention and Exhibition Center. While the content was fascinating, there was also a lot about social media that was quite interesting as well.
Google faces potential challenges, roadblocks in getting Glass adopted
When Jay Zuerndorfer, a student researcher at the Georgia Institute of Technology (Atlanta) received the opportunity to develop an application for Google Glass it was like a dream come true. Zuerndorfer and a research team from Georgia Tech were able to create speech-to-text software for Google Glass that helps hard-of-hearing users with everyday conversations. A hard-of-hearing person wears Glass while a second person speaks directly into a smart phone.